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ERRATUM
In Value in Health, Volume 14, Issue 1, the article, ”Exact Method for Computing Absolute Percent Change in a Dichotomous Outcome
from Meta-Analytic Effect Size: Improving Impact and Cost-Outcome Estimates,” denotes that Delia Hendrie is with the School of
Population Health, University of Western Australia, Perth, Australia. Her correct affiliation is Curtin Health Innovation Research
Institute (CHIRI), Population Health Research, Curtin University, Perth, Western Australia.
ERRATUM
InValue in Health, Volume 13, Issue 8, the article, “Use of aDisease-Specific Instrument in Economic Evaluations:MappingWOMAConto the
EQ-5D Utility Index,” Table 1 was published with some incorrect numbers. This table has been corrected and is available here.
Table 1 – Demographic characteristics and quality of life
scores for the study samples.
Total sample (n257)
Demographic characteristics
Age, mean (SD) 66.5 (7.6)
Female, N (%) 213 (82.9)
Ethnicity, N (%)
Chinese 230 (89.5)
Malay 10 (3.9)
Indian 14 (5.4)
Others 3 (1.2)
Formal education, N (%)
1 year 107 (41.6)
1-6 years 85 (33.1)
7-10 years 46 (17.9)
10 years 14 (5.4)
Married, N (%) 235 (91.4)
Retirees/homemaker, N (%) 222 (86.4)
BMI, mean (SD) 28.2 (4.7)
Years with OA, mean (SD) 6 (5.2)
EQ-5D scores, mean (SD) 0.62 (0.13)
WOMAC scores, mean (SD)
Pain 6.64 (3.38)
Stiffness 3.12 (2.02)
Function 26.24 (10.18)
BMI, body mass index; SD, standard deviation; OA, osteoarthritis;
WOMAC, Western Ontario and McMaster Universities Osteoarthritis
